<DOC>
	<DOCNO>NCT00816894</DOCNO>
	<brief_summary>A first generation clinical study , perform last decade , demonstrate adjuvant treatment compound enhance NMDAR-mediated neurotransmission due agonistic activity NMDAR-associated glycine ( GLY ) site ( e.g . GLY , D-serine ( DSR ) ) lead significant symptom reduction chronic schizophrenia patients.Furthermore , preliminary finding suggest treatment NMDAR-GLY site modulators may also beneficial antipsychotic monotherapy In propose project , three year period , 60 schizophrenia patient fulfill treatment resistance criterion randomly enter 10 week , two phase ( fixed/flexible dose ) , parallel group , double blind control study assess efficacy olanzapine ( OLA ) ( 40 mg/day ) vs. DSR ( 4000 mg/day ) antipsychotic monotherapy.Clinical , neurocognitive , electrophysiological , amino acid ( i.e . GLY , DSR ) level assessment perform study . The specific aim propose project : 1 ) ass efficacy safety DSR new medication treatment refractory schizophrenia , 2 ) ass DSR effect term relevant amino acid serum level , neurocognitive performance , relevant brain electrophysiological parameter . The overall importance propose project consist potential lay foundation innovative type intervention treatment resistant schizophrenia patient .</brief_summary>
	<brief_title>D-serine Monotherapy Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Age 1870 ; 2 . Diagnosis schizophrenia/schizoaffective disorder accord DSMIV criterion . 3 . Stable dose antipsychotic treatment least 4 week ; 4 . Treatment refractoriness accord Kane et al . ( 1988 ) criterion . 1 . Meeting criterion DSMIV Axis I diagnose ; 2 . Substance abuse alcoholism entire lifetime ; 3 . Are judge clinically suicidal homicidal risk ; 4 . Female patient pregnant lactating ; female patient pregnant lactating , sexually active , must use medically accept mean contraception ; 5 . Patients know intolerance OLA treatment fail adequate trial OLA ( least 6 week ) high dos ( 20 mg/day high ) ; 6 . Patients treat depot antipsychotic ECT within eight week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>treatment resistance</keyword>
	<keyword>D-serine</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>treatment refractory schizophrenia</keyword>
</DOC>